{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T02:09:17Z","timestamp":1776910157079,"version":"3.51.2"},"publisher-location":"Cham","reference-count":110,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031970542","type":"print"},{"value":"9783031970559","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":273,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human genetics offers a powerful, causally grounded approach to therapeutic target identification in prion diseases. In this chapter, we examine strategies used to discover and evaluate gene candidates, emphasizing the complementary roles of literature-based hypotheses, expression profiling, cellular screening, and in vivo models. Although candidate selection using cellular and transcriptomic systems has yielded limited translational success due to their inability to fully model the human disease, they remain valuable tools for mechanistic validation. Animal models retain key pathological features of prion disease and provide insights into cell-type-specific and non-cell-autonomous mechanisms, particularly involving glial contributions.<\/jats:p>\n                  <jats:p>\n                    We focus on the translational implications of human genetic discoveries, notably the validation of\n                    <jats:italic>PRNP<\/jats:italic>\n                    as a therapeutic target supported by both Mendelian and GWAS data and the identification of novel risk loci, including\n                    <jats:italic>STX6<\/jats:italic>\n                    and\n                    <jats:italic>GAL3ST1<\/jats:italic>\n                    . Functional evaluation of these genes across multiple experimental platforms has highlighted the complexity of moving from genetic association to therapeutic intervention. Distinctions in prion disease initiation versus propagation versus neurotoxicity stages, and the need for cell- and stage-specific models, are key considerations.\n                  <\/jats:p>\n                  <jats:p>\n                    The chapter concludes by outlining a framework for assessing the relevance for target development, integrating genetic evidence, functional models, and safety data. While\n                    <jats:italic>PRNP-targeting<\/jats:italic>\n                    therapies are now entering clinical trials, further research is needed to delineate mechanisms for other candidates. With advances in multiomic data integration and experimental modeling, genetically guided approaches hold great promise in expanding the therapeutic landscape for these currently untreatable neurodegenerative disorders.\n                  <\/jats:p>","DOI":"10.1007\/978-3-031-97055-9_10","type":"book-chapter","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:37:14Z","timestamp":1758861434000},"page":"219-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Human Genetic Evidence for New Targets in Prion Diseases: Opportunities and Challenges"],"prefix":"10.1007","author":[{"given":"Elizabeth","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Mead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"10_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000725","volume":"18","author":"EA Asante","year":"2020","unstructured":"Asante EA et al (2020) Spontaneous generation of prions and transmissible PrP amyloid in a humanised transgenic mouse model of A117V GSS. PLoS Biol 18:e3000725. https:\/\/doi.org\/10.1371\/journal.pbio.3000725","journal-title":"PLoS Biol"},{"key":"10_CR3","doi-asserted-by":"publisher","unstructured":"Avar M et al (2022) An arrayed genome-wide perturbation screen identifies the ribonucleoprotein hnRNP K as rate-limiting for prion propagation. bioRxiv:2022.2003.2003.482765. https:\/\/doi.org\/10.1101\/2022.03.03.482765","DOI":"10.1101\/2022.03.03.482765"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"31260","DOI":"10.1074\/jbc.M109.004382","volume":"284","author":"C Bach","year":"2009","unstructured":"Bach C et al (2009) Prion-induced activation of cholesterogenic gene expression by Srebp2 in neuronal cells. J Biol Chem 284:31260\u201331269. https:\/\/doi.org\/10.1074\/jbc.M109.004382","journal-title":"J Biol Chem"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"8356","DOI":"10.1074\/jbc.M116.773283","volume":"292","author":"BA Ballmer","year":"2017","unstructured":"Ballmer BA et al (2017) Modifiers of prion protein biogenesis and recycling identified by a highly parallel endocytosis kinetics assay. J Biol Chem 292:8356\u20138368. https:\/\/doi.org\/10.1074\/jbc.M116.773283","journal-title":"J Biol Chem"},{"key":"10_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000421","volume":"5","author":"MA Barria","year":"2009","unstructured":"Barria MA, Mukherjee A, Gonzalez-Romero D, Morales R, De Soto C (2009) Novo generation of infectious prions in vitro produces a new disease phenotype. PLoS Pathog 5:e1000421. https:\/\/doi.org\/10.1371\/journal.ppat.1000421","journal-title":"PLoS Pathog"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"23815","DOI":"10.1073\/pnas.2007406117","volume":"117","author":"I Benilova","year":"2020","unstructured":"Benilova I et al (2020) Highly infectious prions are not directly neurotoxic. Proc Natl Acad Sci 117:23815. https:\/\/doi.org\/10.1073\/pnas.2007406117","journal-title":"Proc Natl Acad Sci"},{"key":"10_CR8","doi-asserted-by":"publisher","unstructured":"Bhamra S et al (2022) Prion propagation is dependent on key amino acids in Charge cluster 2 within the prion protein. bioRxiv:2022.2008.2008.503133. https:\/\/doi.org\/10.1101\/2022.08.08.503133","DOI":"10.1101\/2022.08.08.503133"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"17961","DOI":"10.1074\/jbc.271.30.17961","volume":"271","author":"JB Bock","year":"1996","unstructured":"Bock JB, Lin RC, Scheller RH (1996) A new syntaxin family member implicated in targeting of intracellular transport vesicles. J Biol Chem 271:17961\u201317965. https:\/\/doi.org\/10.1074\/jbc.271.30.17961","journal-title":"J Biol Chem"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1091\/mbc.8.7.1261","volume":"8","author":"JB Bock","year":"1997","unstructured":"Bock JB, Klumperman J, Davanger S, Scheller RH (1997) Syntaxin 6 functions in trans-Golgi network vesicle trafficking. Mol Biol Cell 8:1261\u20131271. https:\/\/doi.org\/10.1091\/mbc.8.7.1261","journal-title":"Mol Biol Cell"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nn.2483","volume":"13","author":"J Bremer","year":"2010","unstructured":"Bremer J et al (2010) Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 13:310\u2013318. https:\/\/doi.org\/10.1038\/nn.2483","journal-title":"Nat Neurosci"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1093\/hmg\/ddu233","volume":"23","author":"CA Brown","year":"2014","unstructured":"Brown CA et al (2014) In vitro screen of prion disease susceptibility genes using the scrapie cell assay. Hum Mol Genet 23:5102\u20135108. https:\/\/doi.org\/10.1093\/hmg\/ddu233","journal-title":"Hum Mol Genet"},{"key":"10_CR13","doi-asserted-by":"publisher","unstructured":"Bryois J et al (2021) Cell-type specific cis-eQTLs in eight brain cell-types identifies novel risk genes for human brain disorders. medRxiv:2021.2010.2009.21264604. https:\/\/doi.org\/10.1101\/2021.10.09.21264604","DOI":"10.1101\/2021.10.09.21264604"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/356577a0","volume":"356","author":"H B\u00fceler","year":"1992","unstructured":"B\u00fceler H et al (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356:577\u2013582. https:\/\/doi.org\/10.1038\/356577a0","journal-title":"Nature"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/0092-8674(93)90360-3","volume":"73","author":"H B\u00fceler","year":"1993","unstructured":"B\u00fceler H et al (1993) Mice devoid of PrP are resistant to scrapie. Cell 73:1339\u20131347. https:\/\/doi.org\/10.1016\/0092-8674(93)90360-3","journal-title":"Cell"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF03403528","volume":"1","author":"H B\u00fceler","year":"1994","unstructured":"B\u00fceler H et al (1994) High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med 1:19\u201330. https:\/\/doi.org\/10.1007\/BF03403528","journal-title":"Mol Med"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1038\/s41467-022-30875-7","volume":"13","author":"G Cadby","year":"2022","unstructured":"Cadby G et al (2022) Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. Nat Commun 13:3124. https:\/\/doi.org\/10.1038\/s41467-022-30875-7","journal-title":"Nat Commun"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13041-020-00610-8","volume":"13","author":"JA Carroll","year":"2020","unstructured":"Carroll JA, Race B, Williams K, Striebel J, Chesebro B (2020) RNA-seq and network analysis reveal unique glial gene expression signatures during prion infection. Mol Brain 13:71. https:\/\/doi.org\/10.1186\/s13041-020-00610-8","journal-title":"Mol Brain"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1128\/jvi.68.4.2135-2141.1994","volume":"68","author":"B Caughey","year":"1994","unstructured":"Caughey B, Brown K, Raymond GJ, Katzenstein GE, Thresher W (1994) Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and Congo red [corrected]. J Virol 68:2135\u20132141. https:\/\/doi.org\/10.1128\/jvi.68.4.2135-2141.1994","journal-title":"J Virol"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13024-018-0270-8","volume":"13","author":"JA Chen","year":"2018","unstructured":"Chen JA et al (2018) Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. Mol Neurodegener 13:41. https:\/\/doi.org\/10.1186\/s13024-018-0270-8","journal-title":"Mol Neurodegener"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/0140-6736(91)93128-V","volume":"337","author":"J Collinge","year":"1991","unstructured":"Collinge J, Palmer MS, Dryden AJ (1991) Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 337:1441\u20131442. https:\/\/doi.org\/10.1016\/0140-6736(91)93128-V","journal-title":"Lancet"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/s0140-6736(06)68930-7","volume":"367","author":"J Collinge","year":"2006","unstructured":"Collinge J et al (2006) Kuru in the 21st century--an acquired human prion disease with very long incubation periods. Lancet 367:2068\u20132074. https:\/\/doi.org\/10.1016\/s0140-6736(06)68930-7","journal-title":"Lancet"},{"key":"10_CR23","doi-asserted-by":"publisher","unstructured":"Concha-Marambio L et al (2023) Development of a methodology for large-scale production of prions for biological and structural studies. Front Mol Biosci 10. https:\/\/doi.org\/10.3389\/fmolb.2023.1184029","DOI":"10.3389\/fmolb.2023.1184029"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"9741","DOI":"10.1073\/pnas.0702662104","volume":"104","author":"NR Deleault","year":"2007","unstructured":"Deleault NR, Harris BT, Rees JR, Supattapone S (2007) Formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA 104:9741\u20139746. https:\/\/doi.org\/10.1073\/pnas.0702662104","journal-title":"Proc Natl Acad Sci USA"},{"key":"10_CR25","doi-asserted-by":"publisher","unstructured":"Dimitriadis A et al (2022) Single-nuclei transcriptomics of mammalian prion diseases identifies dynamic gene signatures shared between species. bioRxiv:2022.2009.2013.507650. https:\/\/doi.org\/10.1101\/2022.09.13.507650","DOI":"10.1101\/2022.09.13.507650"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0882-4010(05)80008-7","volume":"18","author":"K Doh-ura","year":"1995","unstructured":"Doh-ura K, Perryman S, Race R, Chesebro B (1995) Identification of differentially expressed genes in scrapie-infected mouse neuroblastoma cells. Microb Pathog 18:1\u20139","journal-title":"Microb Pathog"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/s41467-024-46360-2","volume":"15","author":"H Era\u00f1a","year":"2024","unstructured":"Era\u00f1a H et al (2024) A Protein Misfolding Shaking Amplification-based method for the spontaneous generation of hundreds of bona fide prions. Nat Commun 15:2112. https:\/\/doi.org\/10.1038\/s41467-024-46360-2","journal-title":"Nat Commun"},{"key":"10_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005623","volume":"12","author":"C Fang","year":"2016","unstructured":"Fang C, Imberdis T, Garza MC, Wille H, Harris DA (2016) A neuronal culture system to detect prion Synaptotoxicity. PLoS Pathog 12:e1005623. https:\/\/doi.org\/10.1371\/journal.ppat.1005623","journal-title":"PLoS Pathog"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00401-023-02583-z","volume":"146","author":"K Fodder","year":"2023","unstructured":"Fodder K et al (2023) Brain DNA methylomic analysis of frontotemporal lobar degeneration reveals OTUD4 in shared dysregulated signatures across pathological subtypes. Acta Neuropathol 146:77\u201395. https:\/\/doi.org\/10.1007\/s00401-023-02583-z","journal-title":"Acta Neuropathol"},{"key":"10_CR30","doi-asserted-by":"publisher","unstructured":"Foliaki ST et al (2020) Pathogenic Prion Protein Isoforms Are Not Present in Cerebral Organoids Generated from Asymptomatic Donors Carrying the E200K Mutation Associated with Familial Prion Disease. Pathogens (Basel, Switzerland) 9. https:\/\/doi.org\/10.3390\/pathogens9060482","DOI":"10.3390\/pathogens9060482"},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/jcp.1041570215","volume":"157","author":"R Gabizon","year":"1993","unstructured":"Gabizon R, Meiner Z, Halimi M, Ben-Sasson SA (1993) Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate. J Cell Physiol 157:319\u2013325. https:\/\/doi.org\/10.1002\/jcp.1041570215","journal-title":"J Cell Physiol"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1136\/jnnp-2012-304820","volume":"84","author":"MJAK Genevieve","year":"2013","unstructured":"Genevieve MJAK et al (2013) Intensity of human prion disease surveillance predicts observed disease incidence. J Neurol Neurosurg Psychiatry 84:1372. https:\/\/doi.org\/10.1136\/jnnp-2012-304820","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/ncomms1282","volume":"2","author":"R Goold","year":"2011","unstructured":"Goold R et al (2011) Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat Commun 2:281. https:\/\/doi.org\/10.1038\/ncomms1282","journal-title":"Nat Commun"},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jmb.2005.03.076","volume":"349","author":"AD Greenwood","year":"2005","unstructured":"Greenwood AD et al (2005) Cell line dependent RNA expression profiles of prion-infected mouse neuronal cells. J Mol Biol 349:487\u2013500. https:\/\/doi.org\/10.1016\/j.jmb.2005.03.076","journal-title":"J Mol Biol"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32:40\u201351. https:\/\/doi.org\/10.1038\/nbt.2786","journal-title":"Nat Biotechnol"},{"key":"10_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010013","volume":"17","author":"D Heinzer","year":"2021","unstructured":"Heinzer D et al (2021) Novel regulators of PrPC biosynthesis revealed by genome-wide RNA interference. PLoS Pathog 17:e1010013. https:\/\/doi.org\/10.1371\/journal.ppat.1010013","journal-title":"PLoS Pathog"},{"key":"10_CR37","doi-asserted-by":"publisher","unstructured":"Hummerich H et al (2023) Genome wide association study of clinical duration and age at onset of sporadic CJD. medRxiv:2023.2010.2017.23297050. https:\/\/doi.org\/10.1101\/2023.10.17.23297050","DOI":"10.1101\/2023.10.17.23297050"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/338342a0","volume":"338","author":"K Hsiao","year":"1989","unstructured":"Hsiao K et al (1989) Linkage of a prion protein missense variant to Gerstmann-Str\u00e4ussler syndrome. Nature 338:342\u2013345. https:\/\/doi.org\/10.1038\/338342a0","journal-title":"Nature"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/msb.2009.10","volume":"5","author":"D Hwang","year":"2009","unstructured":"Hwang D et al (2009) A systems approach to prion disease. Mol Syst Biol 5:252\u2013252. https:\/\/doi.org\/10.1038\/msb.2009.10","journal-title":"Mol Syst Biol"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/pathogens7010005","volume":"7","author":"A Igel-Egalon","year":"2018","unstructured":"Igel-Egalon A, B\u00e9ringue V, Rezaei H, Sibille P (2018) Prion strains and transmission barrier phenomena. Pathogens (Basel, Switzerland) 7:5. https:\/\/doi.org\/10.3390\/pathogens7010005","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"10_CR41","doi-asserted-by":"publisher","unstructured":"Jiang-An Y et al (2022) Robust and versatile arrayed libraries for human genome-wide CRISPR activation, deletion and silencing. bioRxiv:2022.2005.2025.493370. https:\/\/doi.org\/10.1101\/2022.05.25.493370","DOI":"10.1101\/2022.05.25.493370"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/s1474-4422(20)30273-8","volume":"19","author":"E Jones","year":"2020","unstructured":"Jones E et al (2020) Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol 19:840\u2013848. https:\/\/doi.org\/10.1016\/s1474-4422(20)30273-8","journal-title":"Lancet Neurol"},{"key":"10_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106363","volume":"190","author":"E Jones","year":"2024","unstructured":"Jones E et al (2024) Characterisation and prion transmission study in mice with genetic reduction of sporadic Creutzfeldt-Jakob disease risk gene Stx6. Neurobiol Dis 190:106363. https:\/\/doi.org\/10.1016\/j.nbd.2023.106363","journal-title":"Neurobiol Dis"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jmb.2007.11.003","volume":"375","author":"C Julius","year":"2008","unstructured":"Julius C et al (2008) Transcriptional stability of cultured cells upon prion infection. J Mol Biol 375:1222\u20131233. https:\/\/doi.org\/10.1016\/j.jmb.2007.11.003","journal-title":"J Mol Biol"},{"key":"10_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010747","volume":"18","author":"L Kaczmarczyk","year":"2022","unstructured":"Kaczmarczyk L et al (2022) Distinct translatome changes in specific neural populations precede electroencephalographic changes in prion-infected mice. PLoS Pathog 18:e1010747. https:\/\/doi.org\/10.1371\/journal.ppat.1010747","journal-title":"PLoS Pathog"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"19727","DOI":"10.1073\/pnas.1803521116","volume":"116","author":"E Kanata","year":"2019","unstructured":"Kanata E et al (2019) RNA editing alterations define manifestation of prion diseases. Proc Natl Acad Sci 116:19727\u201319735. https:\/\/doi.org\/10.1073\/pnas.1803521116","journal-title":"Proc Natl Acad Sci"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/19336896.2022.2095186","volume":"16","author":"YC Kim","year":"2022","unstructured":"Kim YC, Jeong BH (2022) Transcriptomic analysis identifies novel potential biomarkers and highlights cilium-related biological processes in the early stages of prion disease in mice. Prion 16:84\u201390. https:\/\/doi.org\/10.1080\/19336896.2022.2095186","journal-title":"Prion"},{"key":"10_CR48","doi-asserted-by":"publisher","first-page":"11666","DOI":"10.1073\/pnas.1834432100","volume":"100","author":"PC Kl\u00f6hn","year":"2003","unstructured":"Kl\u00f6hn PC, Stoltze L, Flechsig E, Enari M, Weissmann C (2003) A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci USA 100:11666\u201311671. https:\/\/doi.org\/10.1073\/pnas.1834432100","journal-title":"Proc Natl Acad Sci USA"},{"key":"10_CR49","doi-asserted-by":"publisher","unstructured":"K\u00fc\u00e7\u00fckali F et al (2025) Multiomic analyses direct hypotheses for Creutzfeldt-Jakob disease risk genes. Brain:awaf032. https:\/\/doi.org\/10.1093\/brain\/awaf032","DOI":"10.1093\/brain\/awaf032"},{"key":"10_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-021-01123-8","volume":"9","author":"R Kushwaha","year":"2021","unstructured":"Kushwaha R, Sinha A, Makarava N, Molesworth K, Baskakov IV (2021) Non-cell autonomous astrocyte-mediated neuronal toxicity in prion diseases. Acta Neuropathol Commun 9:22. https:\/\/doi.org\/10.1186\/s40478-021-01123-8","journal-title":"Acta Neuropathol Commun"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/bpa.12694","volume":"29","author":"NTT Le","year":"2019","unstructured":"Le NTT, Wu B, Harris DA (2019) Prion neurotoxicity. Brain Pathol (Zurich, Switzerland) 29:263\u2013277. https:\/\/doi.org\/10.1111\/bpa.12694","journal-title":"Brain Pathol (Zurich, Switzerland)"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.25530","volume":"86","author":"G Leonenko","year":"2019","unstructured":"Leonenko G et al (2019) Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition. Ann Neurol 86:427\u2013435. https:\/\/doi.org\/10.1002\/ana.25530","journal-title":"Ann Neurol"},{"key":"10_CR53","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"J Lonsdale","year":"2013","unstructured":"Lonsdale J et al (2013) The genotype-tissue expression (GTEx) project. Nat Genet 45:580\u2013585. https:\/\/doi.org\/10.1038\/ng.2653","journal-title":"Nat Genet"},{"key":"10_CR54","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41598-018-37715-z","volume":"9","author":"A Majer","year":"2019","unstructured":"Majer A et al (2019) The cell type resolved mouse transcriptome in neuron-enriched brain tissues from the hippocampus and cerebellum during prion disease. Sci Rep 9:1099. https:\/\/doi.org\/10.1038\/s41598-018-37715-z","journal-title":"Sci Rep"},{"key":"10_CR55","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.1090187","volume":"302","author":"G Mallucci","year":"2003","unstructured":"Mallucci G et al (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science (New York, NY) 302:871\u2013874. https:\/\/doi.org\/10.1126\/science.1090187","journal-title":"Science (New York, NY)"},{"key":"10_CR56","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.15252\/embj.201387150","volume":"33","author":"MM Marbiah","year":"2014","unstructured":"Marbiah MM et al (2014) Identification of a gene regulatory network associated with prion replication. EMBO J 33:1527\u20131547. https:\/\/doi.org\/10.15252\/embj.201387150","journal-title":"EMBO J"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"13619","DOI":"10.1074\/jbc.RA118.006186","volume":"294","author":"CE Mays","year":"2019","unstructured":"Mays CE et al (2019) Prion disease is accelerated in mice lacking stress-induced heat shock protein 70 (HSP70). J Biol Chem 294:13619\u201313628. https:\/\/doi.org\/10.1074\/jbc.RA118.006186","journal-title":"J Biol Chem"},{"key":"10_CR58","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1006\/exnr.1997.6740","volume":"149","author":"PA McBride","year":"1998","unstructured":"McBride PA, Wilson MI, Eikelenboom P, Tunstall A, Bruce ME (1998) Heparan sulfate proteoglycan is associated with amyloid plaques and neuroanatomically targeted PrP pathology throughout the incubation period of scrapie-infected mice. Exp Neurol 149:447\u2013454. https:\/\/doi.org\/10.1006\/exnr.1997.6740","journal-title":"Exp Neurol"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/brain\/awl226","volume":"129","author":"S Mead","year":"2006","unstructured":"Mead S et al (2006) Inherited prion disease with six octapeptide repeat insertional mutation\u2013molecular analysis of phenotypic heterogeneity. Brain 129:2297\u20132317. https:\/\/doi.org\/10.1093\/brain\/awl226","journal-title":"Brain"},{"key":"10_CR60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s1474-4422(08)70265-5","volume":"8","author":"S Mead","year":"2009","unstructured":"Mead S et al (2009) Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol 8:57\u201366. https:\/\/doi.org\/10.1016\/s1474-4422(08)70265-5","journal-title":"Lancet Neurol"},{"key":"10_CR61","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/hmg\/ddr607","volume":"21","author":"S Mead","year":"2012","unstructured":"Mead S et al (2012) Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. Hum Mol Genet 21:1897\u20131906. https:\/\/doi.org\/10.1093\/hmg\/ddr607","journal-title":"Hum Mol Genet"},{"key":"10_CR62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1146\/annurev-genet-120213-092352","volume":"53","author":"S Mead","year":"2019","unstructured":"Mead S, Lloyd S, Collinge J (2019) Genetic factors in mammalian prion diseases. Annu Rev Genet 53:117\u2013147. https:\/\/doi.org\/10.1146\/annurev-genet-120213-092352","journal-title":"Annu Rev Genet"},{"key":"10_CR63","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/s1474-4422(22)00082-5","volume":"21","author":"S Mead","year":"2022","unstructured":"Mead S et al (2022) Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurol 21:342\u2013354. https:\/\/doi.org\/10.1016\/s1474-4422(22)00082-5","journal-title":"Lancet Neurol"},{"key":"10_CR64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00441-022-03683-0","volume":"392","author":"RCC Mercer","year":"2023","unstructured":"Mercer RCC, Harris DA (2023) Mechanisms of prion-induced toxicity. Cell Tissue Res 392:81\u201396. https:\/\/doi.org\/10.1007\/s00441-022-03683-0","journal-title":"Cell Tissue Res"},{"key":"10_CR65","doi-asserted-by":"publisher","unstructured":"Minikel EV et al (2016) Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med 8:322ra329. https:\/\/doi.org\/10.1126\/scitranslmed.aad5169","DOI":"10.1126\/scitranslmed.aad5169"},{"key":"10_CR66","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1212\/wnl.0000000000007745","volume":"93","author":"EV Minikel","year":"2019","unstructured":"Minikel EV et al (2019) Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology 93:e125\u2013e134. https:\/\/doi.org\/10.1212\/wnl.0000000000007745","journal-title":"Neurology"},{"key":"10_CR67","doi-asserted-by":"publisher","first-page":"10615","DOI":"10.1093\/nar\/gkaa616","volume":"48","author":"EV Minikel","year":"2020","unstructured":"Minikel EV et al (2020a) Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Res 48:10615\u201310631. https:\/\/doi.org\/10.1093\/nar\/gkaa616","journal-title":"Nucleic Acids Res"},{"key":"10_CR68","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2267-z","volume":"581","author":"EV Minikel","year":"2020","unstructured":"Minikel EV et al (2020b) Evaluating drug targets through human loss-of-function genetic variation. Nature 581:459\u2013464. https:\/\/doi.org\/10.1038\/s41586-020-2267-z","journal-title":"Nature"},{"key":"10_CR69","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson MR et al (2015) The support of human genetic evidence for approved drug indications. Nat Genet 47:856\u2013860. https:\/\/doi.org\/10.1038\/ng.3314","journal-title":"Nat Genet"},{"key":"10_CR1","doi-asserted-by":"publisher","unstructured":"Nihat A et al (2022) Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 93:404. https:\/\/doi.org\/10.1136\/jnnp-2021-327722","DOI":"10.1136\/jnnp-2021-327722"},{"key":"10_CR70","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1128\/jvi.74.1.320-325.2000","volume":"74","author":"N Nishida","year":"2000","unstructured":"Nishida N et al (2000) Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J Virol 74:320\u2013325. https:\/\/doi.org\/10.1128\/jvi.74.1.320-325.2000","journal-title":"J Virol"},{"key":"10_CR71","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/d41573-022-00120-3","volume":"21","author":"D Ochoa","year":"2022","unstructured":"Ochoa D et al (2022) Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat Rev Drug Discov 21:551. https:\/\/doi.org\/10.1038\/d41573-022-00120-3","journal-title":"Nat Rev Drug Discov"},{"key":"10_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105834","volume":"172","author":"D Ojeda-Ju\u00e1rez","year":"2022","unstructured":"Ojeda-Ju\u00e1rez D et al (2022) Prions induce an early arc response and a subsequent reduction in mGluR5 in the hippocampus. Neurobiol Dis 172:105834. https:\/\/doi.org\/10.1016\/j.nbd.2022.105834","journal-title":"Neurobiol Dis"},{"key":"10_CR73","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0140-6736(89)91713-3","volume":"1","author":"F Owen","year":"1989","unstructured":"Owen F et al (1989) Insertion in prion protein gene in familial Creutzfeldt-Jakob disease. Lancet 1:51\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(89)91713-3","journal-title":"Lancet"},{"key":"10_CR74","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/352340a0","volume":"352","author":"MS Palmer","year":"1991","unstructured":"Palmer MS, Dryden AJ, Hughes JT, Collinge J (1991) Homozygous prion protein genotype predisposes to sporadic Creutzfeldt\u2013Jakob disease. Nature 352:340\u2013342. https:\/\/doi.org\/10.1038\/352340a0","journal-title":"Nature"},{"key":"10_CR75","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/bpa.12679","volume":"29","author":"D Pease","year":"2019","unstructured":"Pease D et al (2019) Genome-wide identification of microRNAs regulating the human prion protein. Brain Pathol (Zurich, Switzerland) 29:232\u2013244. https:\/\/doi.org\/10.1111\/bpa.12679","journal-title":"Brain Pathol (Zurich, Switzerland)"},{"key":"10_CR76","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrd4051","volume":"12","author":"RM Plenge","year":"2013","unstructured":"Plenge RM, Scolnick EM, Altshuler D (2013) Validating therapeutic targets through human genetics. Nat Rev Drug Discov 12:581\u2013594. https:\/\/doi.org\/10.1038\/nrd4051","journal-title":"Nat Rev Drug Discov"},{"key":"10_CR77","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1523\/jneurosci.0122-04.2004","volume":"24","author":"M Prinz","year":"2004","unstructured":"Prinz M et al (2004) Intrinsic resistance of oligodendrocytes to prion infection. J Neurosci Off J Soc Neurosci 24:5974\u20135981. https:\/\/doi.org\/10.1523\/jneurosci.0122-04.2004","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10_CR78","doi-asserted-by":"publisher","first-page":"10608","DOI":"10.1073\/pnas.90.22.10608","volume":"90","author":"SB Prusiner","year":"1993","unstructured":"Prusiner SB et al (1993) Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci USA 90:10608\u201310612. https:\/\/doi.org\/10.1073\/pnas.90.22.10608","journal-title":"Proc Natl Acad Sci USA"},{"key":"10_CR79","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1099\/jgv.0.001262","volume":"100","author":"K Qin","year":"2019","unstructured":"Qin K, Zhao L, Solanki A, Busch C, Mastrianni J (2019) Anle138b prevents PrP plaque accumulation in Tg(PrP-A116V) mice but does not mitigate clinical disease. J Gen Virol 100:1027\u20131037. https:\/\/doi.org\/10.1099\/jgv.0.001262","journal-title":"J Gen Virol"},{"key":"10_CR80","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131175","volume":"5","author":"GJ Raymond","year":"2019","unstructured":"Raymond GJ et al (2019) Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight 5:e131175. https:\/\/doi.org\/10.1172\/jci.insight.131175","journal-title":"JCI Insight"},{"key":"10_CR81","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/35081095","volume":"411","author":"GP Saborio","year":"2001","unstructured":"Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411:810\u2013813. https:\/\/doi.org\/10.1038\/35081095","journal-title":"Nature"},{"key":"10_CR82","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/0092-8674(94)90436-7","volume":"77","author":"A Sailer","year":"1994","unstructured":"Sailer A, B\u00fceler H, Fischer M, Aguzzi A, Weissmann C (1994) No propagation of prions in mice devoid of PrP. Cell 77:967\u2013968. https:\/\/doi.org\/10.1016\/0092-8674(94)90436-7","journal-title":"Cell"},{"key":"10_CR83","doi-asserted-by":"publisher","first-page":"7586","DOI":"10.1128\/jvi.69.12.7586-7592.1995","volume":"69","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S et al (1995) Accumulation of proteinase K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt-Jakob disease agent. J Virol 69:7586\u20137592. https:\/\/doi.org\/10.1128\/jvi.69.12.7586-7592.1995","journal-title":"J Virol"},{"issue":"1487","key":"10_CR84","doi-asserted-by":"publisher","first-page":"e1421","DOI":"10.1016\/j.neurobiolaging.2011.10.011","volume":"33","author":"P Sanchez-Juan","year":"2012","unstructured":"Sanchez-Juan P et al (2012) Genome-wide study links MTMR7 gene to variant Creutzfeldt-Jakob risk. Neurobiol Aging 33(1487):e1421\u2013e1488. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.10.011","journal-title":"Neurobiol Aging"},{"key":"10_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123654","volume":"10","author":"P Sanchez-Juan","year":"2014","unstructured":"Sanchez-Juan P et al (2014) A genome wide association study links glutamate receptor pathway to sporadic Creutzfeldt-Jakob disease risk. PLoS One 10:e0123654. https:\/\/doi.org\/10.1371\/journal.pone.0123654","journal-title":"PLoS One"},{"key":"10_CR86","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nature09768","volume":"470","author":"MK Sandberg","year":"2011","unstructured":"Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J (2011) Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470:540\u2013542. https:\/\/doi.org\/10.1038\/nature09768","journal-title":"Nature"},{"key":"10_CR87","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1038\/ncomms5347","volume":"5","author":"MK Sandberg","year":"2014","unstructured":"Sandberg MK et al (2014) Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nat Commun 5:4347. https:\/\/doi.org\/10.1038\/ncomms5347","journal-title":"Nat Commun"},{"key":"10_CR88","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.neuron.2014.04.047","volume":"82","author":"DW Sanders","year":"2014","unstructured":"Sanders DW et al (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82:1271\u20131288. https:\/\/doi.org\/10.1016\/j.neuron.2014.04.047","journal-title":"Neuron"},{"key":"10_CR89","doi-asserted-by":"publisher","first-page":"e83320","DOI":"10.7554\/eLife.83320","volume":"13","author":"D Sangar","year":"2024","unstructured":"Sangar D et al (2024) Syntaxin-6 delays prion protein fibril formation and prolongs presence of toxic aggregation intermediates. eLife 13:e83320. https:\/\/doi.org\/10.7554\/eLife.83320","journal-title":"eLife"},{"key":"10_CR90","doi-asserted-by":"publisher","first-page":"8821","DOI":"10.1128\/jvi.71.11.8821-8831.1997","volume":"71","author":"HM Sch\u00e4tzl","year":"1997","unstructured":"Sch\u00e4tzl HM et al (1997) A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J Virol 71:8821\u20138831. https:\/\/doi.org\/10.1128\/jvi.71.11.8821-8831.1997","journal-title":"J Virol"},{"key":"10_CR91","doi-asserted-by":"publisher","first-page":"e62911","DOI":"10.7554\/eLife.62911","volume":"9","author":"C Scheckel","year":"2020","unstructured":"Scheckel C, Imeri M, Schwarz P, Aguzzi A (2020) Ribosomal profiling during prion disease uncovers progressive translational derangement in glia but not in neurons. eLife 9:e62911. https:\/\/doi.org\/10.7554\/eLife.62911","journal-title":"eLife"},{"key":"10_CR92","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s40478-022-01450-4","volume":"10","author":"JA Slota","year":"2022","unstructured":"Slota JA, Sajesh BV, Frost KF, Medina SJ, Booth SA (2022a) Dysregulation of neuroprotective astrocytes, a spectrum of microglial activation states, and altered hippocampal neurogenesis are revealed by single-cell RNA sequencing in prion disease. Acta Neuropathol Commun 10:161. https:\/\/doi.org\/10.1186\/s40478-022-01450-4","journal-title":"Acta Neuropathol Commun"},{"key":"10_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.918811","volume":"16","author":"JA Slota","year":"2022","unstructured":"Slota JA, Medina SJ, Frost KL, Booth SA (2022b) Neurons and astrocytes elicit brain region specific transcriptional responses to prion disease in the murine CA1 and thalamus. Front Neurosci 16:918811. https:\/\/doi.org\/10.3389\/fnins.2022.918811","journal-title":"Front Neurosci"},{"key":"10_CR94","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.neuron.2019.12.014","volume":"105","author":"HL Smith","year":"2020","unstructured":"Smith HL et al (2020) Astrocyte unfolded protein response induces a specific reactivity state that causes non-cell-autonomous neuronal degeneration. Neuron 105:855\u2013866.e855. https:\/\/doi.org\/10.1016\/j.neuron.2019.12.014","journal-title":"Neuron"},{"key":"10_CR95","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/bf00687367","volume":"77","author":"AD Snow","year":"1989","unstructured":"Snow AD, Kisilevsky R, Willmer J, Prusiner SB, DeArmond SJ (1989) Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol 77:337\u2013342. https:\/\/doi.org\/10.1007\/bf00687367","journal-title":"Acta Neuropathol"},{"key":"10_CR96","doi-asserted-by":"publisher","first-page":"e1008653","DOI":"10.1371\/journal.ppat.1008653","volume":"16","author":"S Sorce","year":"2020","unstructured":"Sorce S et al (2020) Genome-wide transcriptomics identifies an early preclinical signature of prion infection. PLoS Pathog 16:e1008653\u2013e1008653. https:\/\/doi.org\/10.1371\/journal.ppat.1008653","journal-title":"PLoS Pathog"},{"key":"10_CR97","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.4103\/1673-5374.332202","volume":"17","author":"W Tahir","year":"2022","unstructured":"Tahir W, Thapa S, Schatzl HM (2022) Astrocyte in prion disease: a double-edged sword. Neural Regen Res 17:1659\u20131665. https:\/\/doi.org\/10.4103\/1673-5374.332202","journal-title":"Neural Regen Res"},{"key":"10_CR98","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1194\/jlr.R026682","volume":"53","author":"T Takahashi","year":"2012","unstructured":"Takahashi T, Suzuki T (2012) Role of sulfatide in normal and pathological cells and tissues. J Lipid Res 53:1437\u20131450. https:\/\/doi.org\/10.1194\/jlr.R026682","journal-title":"J Lipid Res"},{"key":"10_CR99","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1099\/vir.0.2008\/001255-0","volume":"89","author":"G Tamg\u00fcney","year":"2008","unstructured":"Tamg\u00fcney G et al (2008) Genes contributing to prion pathogenesis. J Gen Virol 89:1777\u20131788. https:\/\/doi.org\/10.1099\/vir.0.2008\/001255-0","journal-title":"J Gen Virol"},{"key":"10_CR100","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/brain\/awt048","volume":"136","author":"AG Thompson","year":"2013","unstructured":"Thompson AG et al (2013) The Medical Research Council prion disease rating scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain 136:1116\u20131127. https:\/\/doi.org\/10.1093\/brain\/awt048","journal-title":"Brain"},{"key":"10_CR101","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01672-22","volume":"97","author":"SM Vallabh","year":"2023","unstructured":"Vallabh SM et al (2023) Therapeutic trial of anle138b in mouse models of genetic prion disease. J Virol 97:e0167222. https:\/\/doi.org\/10.1128\/jvi.01672-22","journal-title":"J Virol"},{"key":"10_CR102","doi-asserted-by":"publisher","first-page":"15637","DOI":"10.1038\/s41598-017-15778-8","volume":"7","author":"S Vanni","year":"2017","unstructured":"Vanni S et al (2017) Differential overexpression of SERPINA3 in human prion diseases. Sci Rep 7:15637. https:\/\/doi.org\/10.1038\/s41598-017-15778-8","journal-title":"Sci Rep"},{"key":"10_CR103","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J et al (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol 125:795\u2013813. https:\/\/doi.org\/10.1007\/s00401-013-1114-9","journal-title":"Acta Neuropathol"},{"key":"10_CR104","doi-asserted-by":"publisher","first-page":"19841","DOI":"10.1074\/jbc.R114.550707","volume":"289","author":"JC Watts","year":"2014","unstructured":"Watts JC, Prusiner SB (2014) Mouse models for studying the formation and propagation of prions. J Biol Chem 289:19841\u201319849. https:\/\/doi.org\/10.1074\/jbc.R114.550707","journal-title":"J Biol Chem"},{"key":"10_CR105","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1073\/pnas.1121556109","volume":"109","author":"JC Watts","year":"2012","unstructured":"Watts JC et al (2012) Spontaneous generation of rapidly transmissible prions in transgenic mice expressing wild-type bank vole prion protein. Proc Natl Acad Sci USA 109:3498\u20133503. https:\/\/doi.org\/10.1073\/pnas.1121556109","journal-title":"Proc Natl Acad Sci USA"},{"key":"10_CR106","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00401-016-1585-6","volume":"132","author":"JC Watts","year":"2016","unstructured":"Watts JC et al (2016) Towards authentic transgenic mouse models of heritable PrP prion diseases. Acta Neuropathol 132:593\u2013610. https:\/\/doi.org\/10.1007\/s00401-016-1585-6","journal-title":"Acta Neuropathol"},{"key":"10_CR107","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/brain\/awn202","volume":"131","author":"TE Webb","year":"2008","unstructured":"Webb TE et al (2008) Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain 131:2632\u20132646. https:\/\/doi.org\/10.1093\/brain\/awn202","journal-title":"Brain"},{"key":"10_CR108","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/ajmg.b.30844","volume":"150b","author":"TE Webb","year":"2009","unstructured":"Webb TE, Whittaker J, Collinge J, Mead S (2009) Age of onset and death in inherited prion disease are heritable. Am J Med Genet B Neuropsychiatr Genet 150b:496\u2013501. https:\/\/doi.org\/10.1002\/ajmg.b.30844","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10_CR109","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41588-020-00773-z","volume":"53","author":"AP Wingo","year":"2021","unstructured":"Wingo AP et al (2021) Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer\u2019s disease pathogenesis. Nat Genet 53:143\u2013146. https:\/\/doi.org\/10.1038\/s41588-020-00773-z","journal-title":"Nat Genet"},{"key":"10_CR110","doi-asserted-by":"publisher","first-page":"11051","DOI":"10.1128\/jvi.78.20.11051-11060.2004","volume":"78","author":"W Xiang","year":"2004","unstructured":"Xiang W et al (2004) Identification of differentially expressed genes in scrapie-infected mouse brains by using global gene expression technology. J Virol 78:11051\u201311060. https:\/\/doi.org\/10.1128\/jvi.78.20.11051-11060.2004","journal-title":"J Virol"}],"updated-by":[{"DOI":"10.1007\/978-3-031-97055-9_14","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000}}],"container-title":["Subcellular Biochemistry","Biomarkers and Therapeutical Targets for Prion Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-97055-9_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:35:25Z","timestamp":1773826525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-97055-9_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031970542","9783031970559"],"references-count":110,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-97055-9_10","relation":{},"ISSN":["0306-0225","2542-8810"],"issn-type":[{"value":"0306-0225","type":"print"},{"value":"2542-8810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"1 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"19 March 2026","order":2,"name":"change_date","label":"Change Date","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"A correction has been published.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}